The oncogenic transcription factor STAT3 is aberrantly activated in 70% of breast cancers,
including nearly all triple-negative breast cancers (TNBCs). Because STAT3 is difficult to …

Cancer nanomedicines and the development of state-of-the-art multifunctional lipid-based
nanoparticles (NPs) has become a fundamental resource in resolving challenging …

Chemotherapy, a conventional breast cancer treatment, has limitations due to its non-
specific mechanisms and undesirable side effects. Lipid-based nanoparticles (LNPs) have …

Cancer stem cells (CSCs) comprise a diminutive population of the tumor but pose major
obstacles in cancer treatment, often their presence being correlated with poor prognosis …

Successful anticancer chemotherapy requires targeting tumors efficiently and further
potential to eliminate cancer stem cell (CSC) subpopulations. Since CD44 is present on …

Lipids are critical for maintaining homeostasis and cellular metabolism. However, the
dysregulation of lipid metabolism contributes to the pathogenesis of chronic inflammatory …

Solid Lipid Nanocarriers (SLNs) offer a promising avenue for breast cancer treatment, a
disease that accounts for 12.5% of global cancer cases. Despite strides in combined …

Nanoparticles‐based drug delivery strategies have been widely researched for cancer
therapy. However, most of them are expected to accumulate in tumor sites via the enhanced …

Immunotherapy combined with chemicals and genetic engineering tools is emerging as a
promising strategy to treat triple-negative breast cancer (TNBC), which is more aggressive …

Adipocytes are the primary cellular components within the tumor microenvironment (TME) of
triple-negative breast cancer (TNBC). Increasing evidence suggests that tumor-associated …